|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim VM and Ahuja N: Early detection of
pancreatic cancer. Chin J Cancer Res. 27:321–331. 2015.PubMed/NCBI
|
|
4
|
Sheffield KM, Crowell KT, Lin YL, Djukom
C, Goodwin JS and Riall TS: Surveillance of pancreatic cancer
patients after surgical resection. Ann Surg Oncol. 19:1670–1677.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chatterjee S, Azad B Behnam and Nimmagadda
S: The intricate role of CXCR4 in cancer. Adv Cancer Res.
124:31–82. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao H, Guo L, Zhao H, Zhao J, Weng H and
Zhao B: CXCR4 over-expression and survival in cancer: A system
review and meta-analysis. Oncotarget. 6:5022–5040. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu PF, Lu ZP, Cai BB, Tian L, Zou C, Jiang
KR and Miao Y: Role of CXCL12/CXCR4 signaling axis in pancreatic
cancer. Chin Med J (Engl). 126:3371–3374. 2013.PubMed/NCBI
|
|
9
|
Cui K, Zhao W, Wang C, Wang A, Zhang B,
Zhou W, Yu J, Sun Z and Li S: The CXCR4-CXCL12 pathway facilitates
the progression of pancreatic cancer Via induction of angiogenesis
and lymphangiogenesis. J Surg Res. 171:143–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bilimoria KY, Bentrem DJ, Merkow RP,
Tomlinson JS, Stewart AK, Ko CY and Talamonti MS: Application of
the pancreatic adenocarcinoma staging system to pancreatic
neuroendocrine tumors. J Am Coll Surg. 205:558–563. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sharma C, Eltawil KM, Renfrew PD, Walsh MJ
and Molinari M: Advances in diagnosis, treatment and palliation of
pancreatic carcinoma: 1990–2010. World J Gastroenterol. 17:867–897.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang YM, Li G, Sun BC, Zhao XL and Zhou
ZK: Study on the relationship between cxcr4 expression and
perineural invasion in pancreatic cancer. Asian Pac J Cancer Prev.
15:4893–4896. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu C, Zhao H, Chen H and Yao Q: CXCR4 in
breast cancer: Oncogenic role and therapeutic targeting. Drug Des
Devel Ther. 9:4953–4964. 2015.PubMed/NCBI
|
|
17
|
Tsai MF, Chang TH, Wu SG, Yang HY, Hsu YC,
Yang PC and Shih JY: EGFR-L858R mutant enhances lung adenocarcinoma
cell invasive ability and promotes malignant pleural effusion
formation through activation of the CXCL12-CXCR4 pathway. Sci Rep.
5:135742015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng L, Shang Y, Guo S, Liu C, Zhou L, Sun
Y, Nie Y, Fan D, Lu Y and Guo X: Ran GTPase protein promotes
metastasis and invasion in pancreatic cancer by deregulating the
expression of AR and CXCR4. Cancer Biol Ther. 15:1087–1093. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X,
Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7
chemokine axis and cancer progression. Cancer Metastasis Rev.
29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wehler T, Wolfert F, Schimanski CC, Gockel
I, Herr W, Biesterfeld S, Seifert JK, Adwan H, Berger MR, Junginger
T, et al: Strong expression of chemokine receptor CXCR4 by
pancreatic cancer correlates with advanced disease. Oncol Rep.
16:1159–1164. 2006.PubMed/NCBI
|
|
21
|
Krieg A, Riemer JC, Telan LA, Gabbert HE
and Knoefel WT: CXCR4-A prognostic and clinicopathological
biomarker for pancreatic ductal adenocarcinoma: A Meta-Analysis.
PLoS One. 10:e01301922015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou Y, Larsen PH, Hao C and Yong VW:
CXCR4 is a major chemokine receptor on glioma cells and mediates
their survival. J Brol Chem. 277:49481–49487. 2002.
|
|
23
|
Lapidot T and Kollet O: The essential
roles of the chemokine SDF-1 and its receptor CXCR4 in human stem
cell homing and repopulation of tranaplanted immune-deficient
NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia. 16:1992–2003. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Salmaggi A, Gelati M, Pollo B, Frigerio S,
Eoli M, Silvani A, Broggi G, Ciusani E, Croci D, Boiardi A and De
Rossi M: CXCL12 in malignant glial tumors: A possible role in
angiogenesis and cross-talk between endothelial and tumoral cells.
J Neurooncol. 67:305–317. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhong W, Chen W, Zhang D, Sun J, Li Y,
Zhang J, Gao Y, Zhou W and Li S: CXCL12/CXCR4 axis plays pivotal
roles in the organ-specific metastasis of pancreatic
adenocarcinoma: A clinical study. Exp Ther Med. 4:363–369. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zou W, Machelon V, Coulomb-L'Hermin A,
Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I,
Gordon A, et al: Stromal-derived factor-1 in human tumors recruits
and alters the function of plasmacytoid precursor dendritic cells.
Nat Med. 7:1339–1346. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Salvucci O, Yao L, Villalba S, Sajewicz A,
Pittaluga S and Tosato G: Regulation of endothelial cell branching
morphogenesis by endogenous chemokine stromal-derived factor-1.
Blood. 99:2703–2711. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Ma Q, Li P, Sha H, Li X and Xu J:
Aberrant expression of CXCR4 and β-catenin in pancreatic cancer.
Anticancer Res. 33:4103–4110. 2013.PubMed/NCBI
|
|
29
|
Lane WJ, Dias S, Hattori K, Heissig B,
Choy M, Rabbany SY, Wood J, Moore MA and Rafii S: Stromal-derived
factor 1-induced megakaryocyte migration and platelet production is
dependent on matrix metalloproteinases. Blood. 96:4152–4159.
2000.PubMed/NCBI
|
|
30
|
Yuecheng Y and Xiaoyan X: Stromal-cell
derived factor-1 regulates epithelial ovarian cancer cell invasion
by activating matrix metalloproteinase-9 and matrix
metalloproteinase-2. Eur J Cancer Prev. 16:430–435. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Ma Q, Liu Q, Yu H, Zhao L, Shen S
and Yao J: Blockade of SDF-1/CXCR4 signalling inhibits pancreatic
cancer progression in vitro via inactivation of canonical Wnt
pathway. Br J Cancer. 99:1695–1703. 2008. View Article : Google Scholar : PubMed/NCBI
|
